Pill Poppers

Litke, Cara
March 2008
Allure;Mar2008, p40
The article focuses on the launch of Alli, the first weight-loss pill for use without a prescription approved by the U.S. Food & Drug Administration. According to the author, the drug works by blocking the absorption of a quarter of the fat in all ingested foods. The fat passes through the body and can cause side effects such as frequent bowel movements. Although it was designed for clinically overweight people, the pill also seems to appeal to women with just a few pounds to lose.


Related Articles

  • The Skinny on Alli. Barr, Naomi // O, The Oprah Magazine;Jul2007, Vol. 8 Issue 7, p122 

    The article offers information on Alli, a weight loss pill that has been approved by the U.S. Food and Drug Administration. The drug, which can be purchased without prescription, prevents the body from digesting about 25 percent of the fat in food. In some studies, people who took the pill while...

  • OTC Product: Alli. Marshall, Leisa L. // Journal of the American Pharmacists Association: JAPhA;Jul/Aug2007, Vol. 47 Issue 4, p544 

    The article offers information on Alli, an over-the-counter agent launched by GlaxoSmithKline in the U.S. used for obesity management. It notes that each capsule contains 60 milligrams of orlistat and used for overweight and obese adults. It states that the drug was the first weight loss product...

  • Glaxo offers by-the-book weight loss plan for Alli. McGuire, Stephen // Medical Marketing & Media;Mar2007, Vol. 42 Issue 3, p8 

    The article focuses on the launching of Alli, an over-the-counter (OTC) weight-loss drug, by Glaxosmithkline in the U.S. It will also distribute a book featuring recipes and lifestyle tips. The firm's spokesperson Brian Jones discloses that the book will be sold in retail outlets including Kmart...

  • Aristolochic acid nephropathy: A worldwide problem. Debelle, Frédéric D; Vanherweghem, Jean-Louis; Nortier, Joëlle L // Kidney International;Jul2008, Vol. 74 Issue 2, p158 

    Aristolochic acid nephropathy (AAN), a progressive renal interstitial fibrosis frequently associated with urothelial malignancies, was initially reported in a Belgian cohort of more than 100 patients after the intake of slimming pills containing a Chinese herb, Aristolochia fangchi. Although...

  • Is the magic bullet just around the corner? Ardell, Donald // Active Living;May2006, Vol. 15 Issue 3, p12 

    Reports on the failure of Acomplia, the alleged wonder pill that is supposed to promote weight loss and smoking cessatioin, which in turn enables the cardiovascular benefits, to get its first U.S. Food and Drug Administration approval. Reason for the disapproval of the drug; Concerns about the...

  • Vivus Soars on Positive View of Obesity Pill.  // MondayMorning;2/27/2012, Vol. 20 Issue 9, p1 

    The article presents information on the new weight loss pill called Qnexa, formulated by Vivas Inc. which will become the first pill to be approved by the U.S. in last 13 years. It reports that the U.S. Food and Drug Administration has voted in favor of the drug approval. It is further stated...

  • Third weight-loss drug approved for obese, overweight adults. Talsma, Julia // Drug Topics;Oct2014, Vol. 158 Issue 10, p38 

    The article reports the approval of Contrave by the Food and Drug Administration (FDA) for use by obese and overweight adults who need to lose weight. Contrave is a weight management drug that combines naltrexone HCl and bupropion HCl in an extended-release formulation and prescribed for...

  • A supplement-savvy site.  // Health (Time Inc. Health);Jul/Aug2002, Vol. 16 Issue 6, p76 

    Details several issues and tips regarding pills and supplements that can be found in the Web site of the U.S. Food and Drug Administration.

  • FDA questioned on '08 Motrin recall. Lillis, Mike // Hill;9/22/2010, Vol. 17 Issue 102, p22 

    The article reports on the decision of the House Oversight Committee for the Food and Drug Administration to attest on its role in the Motrin pills phantom recall in the U.S.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics